Physician profile
Paul E Feuerstadt
NPI 1386975928
$1,034,674.10
in general payments reported to CMS, 2019-2025
44 companies · $270K in 2025
The $270K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $26K · 2021: $85K · 2022: $87K · 2023: $195K · 2024: $304K · 2025: $270K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $404K · Consulting Fee: $309K · Travel and Lodging: $37K · Food and Beverage: $9,838 · Honoraria: $6,400 · Education: $1,240 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $404,247.20 |
| Consulting Fee | $309,148.45 |
| Travel and Lodging | $36,862.14 |
| Food and Beverage | $9,838.34 |
| Honoraria | $6,400.00 |
| Education | $1,239.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $399,136.52 | 2019-2025 | Rebyota |
| Genzyme Corporation | $220,959.35 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $132,313.05 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $84,738.18 | 2022-2025 | Vowst |
| Rebiotix INC. | $81,112.51 | 2024 | Rebyota |
| Merck Sharp & Dohme LLC | $55,693.55 | 2019-2024 | Dificid |
| Ferring Microbiome INC. | $21,414.59 | 2025 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $19,304.40 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Astrazeneca Uk Limited | $5,225.00 | 2024 | |
| Roche Diagnostics Corporation | $4,624.24 | 2019-2020 | |
| Abbvie INC. | $4,164.28 | 2019-2025 | |
| Ferring Pharmaceuticals Ltd | $1,600.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $1,516.04 | 2023-2025 | Linzess |
| Pfizer International LLC | $1,000.00 | 2020 | |
| Mahana Therapeutics, INC. | $411.13 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $258.03 | 2024-2025 | Ibsrela |
| Allergan, INC. | $181.19 | 2019 | |
| Celgene Corporation | $136.83 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.37 | 2019-2023 | Trulance |
| Lilly USA, LLC | $97.47 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $94.12 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $82.91 | 2023 | |
| Medtronic, INC. | $69.09 | 2025 | Barrx |
| Qol Medical, LLC | $65.40 | 2025 | Sucraid |
| Braintree Laboratories, INC. | $51.06 | 2021-2025 | Suflave, Sutab |
| Pfizer INC. | $47.30 | 2024-2025 | |
| Janssen Biotech, INC. | $37.32 | 2019 | |
| Fresenius Kabi USA, LLC | $27.00 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $25.21 | 2024 | Resmetirom |
| Portola Pharmaceuticals, LLC | $24.38 | 2020 | |
| Digestive Care, INC. | $21.75 | 2025 | Pertzye |
| Glaxosmithkline, LLC. | $20.99 | 2020 | |
| Intra-Sana Laboratories | $20.17 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ipsen Biopharmaceuticals, INC | $18.88 | 2025 | Iqirvo |
| Pentax of America, INC. | $17.60 | 2022 | |
| Tempus Ai, INC | $16.38 | 2024 | Xt Cdx |
| Intercept Pharmaceuticals, INC. | $13.73 | 2023 | Ocaliva |
| Olympus America INC. | $12.08 | 2019 | |
| Seres Therapeutics, INC. | $10.00 | 2024 | Vowst |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Feuerstadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.